After having floated its Alcon subsidiary, specializing in ophthalmology, on the stock market in 2019, Novartis is considering parting with Sandoz, its generic drug business.
The Swiss giant announced on Tuesday
"to start a strategic review"
which should continue until the end of 2022.
"It is the right time to ask what is the best option for this activity",
declared Vas Narasimhan, the CEO of Novartis, presenting the laboratory's quarterly results.
Read also
The call for help from generic drug manufacturers
Novartis has been working on the future of this division, which represents 18.5% of its turnover for several years.
Upon his arrival at the head of the group in February 2018, Vas Narasimhan had undertaken to refocus Big Pharma around innovative drugs.
The activity requires increasingly costly and risky R&D investments.
63% of Novartis sales now come from its first twenty drugs.
In September 2018, the laboratory had already attempted to prune the
This article is for subscribers only.
You have 73% left to discover.
To cultivate one's freedom is to cultivate one's curiosity.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in
